{"article_title": "Study Finds Biodesix's Veristrat Offers Potential Savings in Lung Cancer Treatment", "article_keywords": ["week", "patient", "cancer", "study", "veristrat", "finds", "offers", "savings", "potential", "lung", "treatment", "using", "total", "biodesixs", "york"], "article_url": "https://www.genomeweb.com/proteomics-protein-research/study-finds-biodesixs-veristrat-offers-potential-savings-lung-cancer", "article_text": "NEW YORK (GenomeWeb) \u2013 A health economic study sponsored by Biodesix has found that the company's Veristrat lung cancer test could potentially decrease patient treatment costs.\n\nPublished this week in the journal Lung Cancer, the study found that using Veristrat to guide patient therapy in cases of advanced non-small cell lung cancer decreased the total lifetime direct medical cost per patient by $135.", "article_metadata": {"description": "The study found that using Veristrat to guide patient therapy decreased the total lifetime direct medical cost per patient by $135.", "generator": "Drupal 7 (http://drupal.org)", "og": {"site_name": "GenomeWeb", "description": "The study found that using Veristrat to guide patient therapy decreased the total lifetime direct medical cost per patient by $135.", "title": "Study Finds Biodesix's Veristrat Offers Potential Savings in Lung Cancer Treatment", "url": "https://www.genomeweb.com/proteomics-protein-research/study-finds-biodesixs-veristrat-offers-potential-savings-lung-cancer", "image": "https://www.genomeweb.com/sites/default/themes/siteskin/inc/images/ogimg-default2.png", "type": "article"}, "twitter": {"url": "https://www.genomeweb.com/proteomics-protein-research/study-finds-biodesixs-veristrat-offers-potential-savings-lung-cancer", "card": "summary", "title": "Study Finds Biodesix's Veristrat Offers Potential Savings in Lung Cancer Treatment"}, "HandheldFriendly": "True", "msvalidate.01": "589DA07A6166C67D948C23FD502C6942", "viewport": "width=device-width, initial-scale=1.0"}, "article_summary": "NEW YORK (GenomeWeb) \u2013 A health economic study sponsored by Biodesix has found that the company's Veristrat lung cancer test could potentially decrease patient treatment costs.\nPublished this week in the journal Lung Cancer, the study found that using Veristrat to guide patient therapy in cases of advanced non-small cell lung cancer decreased the total lifetime direct medical cost per patient by $135."}